2014


To access this material please log in or register

Register Authorize
2014/№6

Beta-adrenoblockers and heart-rate-lowering therapy: practitioner’s view

Tarlovskaya E.I.
State Budgetary Educational Institution of Higher Professional Education “Kirov State Medical Academy” of the RF Ministry of Health Care, K. Marx 112, Kirov 610027

Keywords: hyperpiesis, beta-adrenergic blocker agents, myocardial infarction, 
coronary heart disease, heart-rate-lowering therapy, heart failure


DOI: 10.18087/rhj.2014.6.2028

This review presents up-to-date data on the use of β-adrenoblockers (AB) as heart-rate-lowering therapy for various cardiovascular diseases (CVDs). The material is provided in consistency with recent Guidelines of international cardiological societies. The authors highlighted statements with higher class and level of evidence and also presented alternatives opinions.
  1. Bemelmans RH, Visseren FL. The resting heart rate. Ned Tijdschr Geneeskd. 2014;158 (13):A6931.
  2. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372 (9641):8 17–21.
  3. Pepine CJ, Handberg-Thurmond E, Marks RG et al. Rationale and design of the International Verapamil SR / Trandolapril Study (INVEST): an internet – based randomized trial in coronary artery disease patients with hypertension. JACC. 1998 Nov 1; (32) (5):1228–37.
  4. Achenbach S, Andreotti F, Arden C et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013 Oct 7;34 (38):2949–3003.
  5. Bangalore S, Messerli FH, Ou FS et al. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J. 2010 Mar;31 (5):552–60.
  6. Böhm M, Swedberg K, Komajda M, Borer JS Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010 Sep 11;376 (9744):886–94.
  7. Bohm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013 Jan;102 (1):11–22.
  8. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012 Jul;33 (14):1787–847.
  9. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) Журнал Сердечная Недостаточность. 2013;14 (7):379–472.
  10. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs. 2006;66 (2):133–44.
  11. Palatini P, Reboldi G, Beilin LJ et al. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol. 2013 Sep 30;168 (2):1490–5.
  12. Salles GF, Cardoso CR, Fonseca LL et al. Prognostic significance of baseline heart rate and its interaction with beta-blocker use in resistant hypertension: a cohort study. Am J Hypertens. 2013 Feb;26 (2):218–26.
  13. Julius S, Palatini P, Kjeldsen SE et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012 Mar 1;109 (5):685–92.
  14. Okin PM, Kjeldsen SE, Julius S et al. Effect of changing heart rate during treatment of hypertension on incidence of heart failure. Am J Cardiol. 2012 Mar 1;109 (5):699–704.
  15. Okin PM, Wachtell K, Kjeldsen SE et al. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol. 2008 Dec;1 (5):337–43.
  16. Palatini P, Thijs L, Staessen JA et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002 Nov 15;162 (20):2313–21.
  17. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008 Oct 28;52 (18):1482–9.
  18. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007 Aug 14;50 (7):563–72.
  19. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol. 2013 Jan;75 (1):79–92.
  20. Wiysonge CS, Bradley HA, Volmink J et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012;8: CD002003.
  21. De Caterina AR, Leone AM. Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol. 2010 May 15;105 (10):1433–8.
  22. Warmack TS, Estes MA, Heldenbrand S, Franks AM. Beta-adrenergic antagonists in hypertension: a review of the evidence. Ann Pharmacother. 2009 Dec;43 (12): 2031–43.
  23. Chrysant SG, Chrysant GS. Current status of β-blockers for the treatment of hypertension: an update. Drugs Today. 2012 May;48 (5):353–66.
  24. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH / ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 Jul 21;34 (28):2159–219.
  25. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009 May 23;338 (7705):1245.
  26. Bangalore S, Steg G, Deedwania P et al. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 3;308 (13):1340–9.
  27. Козиолова Н. А. Бета-адреноблокаторы в лечении инфаркта миокарда и стабильной ишемической болезни сердца: спорные вопросы и неопровержимые доказательства. Фарматека. 2013;13:12–21.
  28. Гиляревский С. Р., Орлов В. А., Кузьмина И. М. и др. Изменение представлений о роли бета-блокаторов в лечении сердечно-сосудистых заболеваний. Русский медицинский журнал. 2013;4:231–6.
  29. Bangalore S, Makani H, Radford M et al. Clinical Outcomes with β-blockers for Myocardial Infarction A Meta-Analysis of Randomized Trials. Am J Med. 2014 Oct;127 (10):939–53.
  30. Roberts R, Rogers WJ, Mueller HS et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation. 1991 Feb;83 (2):422–37.
  31. Van de Werf F, Janssens L, Brzostek T et al. Short-term effect of early intravenous treatment with beta-adrenergic blocking agents or a specific bradycardia agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 1993 Aug;22 (2):407–16.
  32. Barron HV, Rundle AC, Gore JM et al. Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Am J Cardiol. 2000 Feb 1;85 (3):294–8.
  33. Emery M, López-Sendón J, Steg PG et al. Patterns of use and potential impact of early beta-blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events. Am Heart J. 2006 Dec;152 (6):1015–21.
  34. Miller CD, Roe MT, Mulgund J et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med. 2007 Aug;120 (8):685–92.
  35. Gunnell AS, Einarsdóttir K, Sanfilippo F et al. Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study. Heart. 2013 Sep;99 (18):1353–8.
  36. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF / AHA / ACP / AATS / PCNA / SCAI / STS Guideline for the diagnosis and mana­gement of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012 Dec 18;60 (24):e44‑e164.
  37. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presen­ting without persistent ST-segment elevation. Eur Heart J. 2011 Dec;32 (23):2999–3054.
  38. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996 May 23;334 (21):1349–55.
  39. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies-CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J. 2002 Feb;143 (2):301–7.
  40. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 Jul 5;362 (9377):7–13.
  41. Domanski MJ, Krause-Steinrauf H, Massie BM et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003 Oct;9 (5):354–63.
  42. Verbrugge FH, Duchenne J, Bertrand PB et al. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions. Am J Cardiol. 2013 Dec 15;112 (12):1913–20.
  43. Franke J, Wolter JS, Meme L et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol. 2013 Jan;102 (1):23–31.
  44. Rienstra M, Damman K, Mulder BA et al. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. J Am Coll Cardiol HF. 2013 Feb;1 (1):21–8.
  45. Kao DP, Davis G, Aleong R et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar;15 (3):324–33.
  46. Stankovic I, Neskovic AN, Putnikovic B et al. Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure – insight from the Cardiac Insufficiency Bisoprolol Study in Elderly. Int J Cardiol. 2012 Nov 29;161 (3):160–5.
  47. Stecker EC, Fendrick AM, Knight BP, Aaronson KD. Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia. Аm Heart J. 2006 Apr;151 (4):820–8.
Tarlovskaya E. I. Beta-adrenoblockers and heart-rate-lowering therapy: practitioner’s view. Russian Heart Journal. 2014;13 (6):383–388

To access this material please log in or register

Register Authorize
Ru En